non prescription glp-1 Updates for Employers: Demand, Shortages, and Cost Comparing Ozempic, Wegovy and Other

Structure Therapeutics is among the most advanced challengers, with its oral GLP-1 receptor agonist aleniglipron generating Phase 2 data that has drawn significant industry attention

The SEMALEAN trial found lean mass declined then stabilised while handgrip strength improved by 4.5 kg and sarcopenic obesity prevalence fell from 49% to 33% over twelve months

Ozempic is FDA-approved for type 2 diabetes treatment but may be prescribed off-label for weight loss at a provider's discretion and professional judgement

The 5x half-life rule By the time five half-lives have passed, only about 1 to 3 percent remains, which is considered negligible